Microbes play a decisive role in respiratory health by both directly infecting the respiratory tract and exacerbating respiratory tract diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and asthma. While opportunistic pathogens—pathobionts—frequently colonize the upper respiratory tract asymptomatically, invasion to the lungs causes pneumonia due to the ensuing immune response. Bacterial-viral co-infections, such as S. pneumoniae co-infection with influenza A virus, can result in worsened disease due to overwhelming inflammation. In contrast, commensal bacteria from both the gut and upper respiratory tract play important roles in protecting against respiratory tract infection. This collection will highlight methods tailored to investigating host-pathogen interactions in the respiratory tract. These include methods to interrogate the immune response to respiratory tract colonization and infection by bacterial, viral and fungal pathogens. Approaches to study respiratory tract co-infections and the role of the microbiota in maintaining respiratory tract immune homeostasis are also encouraged. Small animal models are critical for investigating dynamic relationships between microbes and respiratory tract immunity. In such models, pathogen burdens quantified by growth assays or qPCR can be paired with techniques to analyze the immune response including flow cytometry, ELISA, qRT-PCR, and immunohistochemistry. Cell culture or ex vivo models, including primary immune cell cultures and opsonophagocytosis assays, permit analysis of specific immune cells and signaling pathways involved in pathogen clearance. Both whole systems and reductive approaches are important for progressing our understanding of the host-pathogen dynamic in the respiratory tract.
0 Views
•
Cited by 1
•
2021
•
Lovisa Dousha1,2, Roleen Sharma1,2, Steven Lim2,3, James Ngui2,4, Ashley M. Buckle5, Paul T. King1,2
1Monash Lung and Sleep, Monash Medical Centre, 2Monash University Department of Medicine, Monash Medical Centre, 3Flow Cytometry Science Technology Platform, Francis Crick Institute, 4Clinical Immunology, Monash Medical Centre, 5Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University
0 Views
•
Cited by 1
•
2020
•
0 Views
•
Cited by 23
•
2020
•
Carlos Victor Montefusco-Pereira*1,2, Justus C. Horstmann*1,2, Thomas Ebensen3, Christoph Beisswenger4, Robert Bals4, Carlos A. Guzmán3, Nicole Schneider-Daum1, Cristiane de Souza Carvalho-Wodarz1, Claus-Michael Lehr1,2
1Department of Drug Delivery, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), 2Department of Pharmacy, Saarland University, 3Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, 4Department of Internal Medicine V - Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital
0 Views
•
Cited by 8
•
2020
•
Lindsay Jackson1, William DePas2, Amanda J. Morris1, Kevin Guttman1, Yvonne C W Yau1,3, Valerie Waters1,4
1Translational Medicine, Hospital for Sick Children, 2Center for Microbial Pathogenesis, Department of Pediatrics, University of Pittsburgh, 3Microbiology, Department of Pediatric Laboratory Medicine, Hospital for Sick Children, 4Infectious Diseases, Department of Pediatrics, Hospital for Sick Children
0 Views
•
Cited by 6
•
2020
•
0 Views
•
Cited by 3
•
2022
•
Alexsandra Lenhard*1, Basma H. Joma*2,3, Nalat Siwapornchai2, Anders P. Hakansson4, John M. Leong2,5, Elsa N. Bou Ghanem1
1Department of Microbiology and Immunology, University at Buffalo School of Medicine, 2Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 3Graduate Program in Immunology, Tufts Graduate School of Biomedical Sciences, 4Department of Translational Medicine, Lund University, 5Stuart B. Levy Center for the Integrated Management of Antimicrobial Resistance, Tufts University